Kenzie MacIsaac, Ph.D.
Dr. MacIsaac is a Partner on the Cure investment team and serves as an interim operating executive for
Cure’s portfolio companies.
Every day we are learning more and more about what makes us all tick.
Dr. MacIsaac is a Partner at Cure Ventures. Kenzie’s career spans over 13 years in drug discovery working at the
cutting edge of genetics, genomics, and bioinformatics to solve pressing problems in human health.
Prior to joining Cure Ventures, Dr. MacIsaac served as a Senior Director at Bristol Myers Squibb where he built out
the oncology precision medicine and bioinformatics capability at their Kendall Square discovery site, played a central
role in genetically driven new target identification efforts, and made key contributions to the understanding of drug
resistance, including Opdivo and Yervoy combinations. Prior to BMS, Kenzie led Translational Bioinformatics at Fog Pharma
with responsibility for their computational biology platform.
From 2014-2018 Dr. MacIsaac was a group leader at the Novartis Institutes for Biomedical Research. While at NIBR
Oncology he helped develop their strategy for using genomic data to immunophenotype cancer and drive patient selection
and translational research efforts for oncology assets.
From 2009-2014 Dr. MacIsaac was a scientist at Merck Research Laboratories in their Genetics and Pharmacogenomics
department, focused on the identification of genetically validated targets in immunology and respiratory disease.
Dr. MacIsaac’s academic background includes a Ph.D. in Computer Science from the Massachusetts Institute of
Technology where he studied under Dr. Ernest Fraenkel, a M.A.Sc in Electrical Engineering from the University
of Toronto, and a B.Eng in Electrical Engineering from Carleton University where he graduated with
Go back to our team